Sequel Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://sequelpharma.com
Clinical Trials
7
Active:4
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (75.0%)Phase 1
1 (25.0%)Effects of Intravenous K201 on the Restoration of Sinus Rhythm in Subjects With Symptomatic Atrial Fibrillation
- First Posted Date
- 2010-12-14
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Sequel Pharmaceuticals, Inc
- Target Recruit Count
- 80
- Registration Number
- NCT01259622
Phase 2 Study of Oral K201 for Prevention of AF Recurrence
Phase 2
Terminated
- Conditions
- Atrial Fibrillation
- Interventions
- Drug: K201 TabletDrug: Placebo Tablet
- First Posted Date
- 2010-02-12
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Sequel Pharmaceuticals, Inc
- Target Recruit Count
- 300
- Registration Number
- NCT01067833
Study of K201 Injection on Restoration of Sinus Rhythm in Subjects Who Are in Atrial Fibrillation
Phase 2
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- Drug: K201 Injection
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2010-01-08
- Lead Sponsor
- Sequel Pharmaceuticals, Inc
- Target Recruit Count
- 153
- Registration Number
- NCT00626652
News
No news found